AKT1 and endothelial dysfunction: In the future, we will further explore the mechanism by which biochanin A can improve endothelial dysfunction by binding to its target proteins AKT1 and TNF-α, to provide theoretical support for the possibility of biochanin A as a clinical therapeutic drug.